Dianthus Therapeutics (DNTH) Change in Receivables (2025)

Dianthus Therapeutics' (DNTH) quarterly Change in Receivables came in at $5.0 million in Q3 2025, up 616.23% quarter-over-quarter from -$961000.0 in Q2 2025.

Dianthus Therapeutics (DNTH) Change in Receivables (2025) Analysis & Trends

Dianthus Therapeutics' Change in Receivables history runs 1 years deep, the most recent figure standing at $5.0 million for Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 75.30 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -39.80 Mn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -1.20 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Dianthus Therapeutics 3.92 Bn 3.51 Bn - -

Historic Data

Download Data
DateValue
Sep 30, 2025 4.96 Mn
Sep 30, 2025 4.96 Mn
Jun 30, 2025 -961,000.00
Jun 30, 2025 -961,000.00
Mar 31, 2025 1.00 Mn
Mar 31, 2025 1.00 Mn